"Entry point" benefit is relative to ones prior entry points. Clearly LTSH with prior dilution baked in are more vulnerable than the more recent investors. In my view, they're doing what all bios do, licking the can down the road, hoping data provides more options.
The 60 mil cost to get to AXAL 2022 is being replaced by redesigned AXAL 2020 cost of 25-30 million. Huh? Bringing cash burn down to 48 mil from 80 mil, old old news. Harping on 12 mos cash is bs, pure and simple. They gotta run the tightrope between data coming, fear of that data, and the promise of the data. Of course thats nothing new. Pretty cagey responses to dilution and debt financing. One way or the other its gonna happen.
Not a damn thing has fundamentally changed here for LTSH in my view. How could it without putting points on the board?